Jayson Bedford
Stock Analyst at Raymond James
(3.93)
# 657
Out of 4,711 analysts
295
Total ratings
57.19%
Success rate
7.63%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Upgrades: Outperform | $170 | $169.52 | +0.28% | 5 | Nov 6, 2024 | |
| DXCM DexCom | Maintains: Strong Buy | $115 → $99 | $80.04 | +23.69% | 30 | Oct 25, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $128 → $123 | $107.12 | +14.82% | 6 | Oct 14, 2024 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $500 → $540 | $524.43 | +2.97% | 7 | Oct 14, 2024 | |
| PODD Insulet | Maintains: Outperform | $213 → $260 | $266.57 | -2.46% | 25 | Oct 14, 2024 | |
| ABT Abbott Laboratories | Maintains: Outperform | $122 → $129 | $114.23 | +12.93% | 27 | Oct 14, 2024 | |
| ICUI ICU Medical | Maintains: Outperform | $158 → $190 | $156.82 | +21.16% | 19 | Sep 12, 2024 | |
| BSX Boston Scientific | Maintains: Strong Buy | $91 → $94 | $88.95 | +5.68% | 22 | Sep 4, 2024 | |
| BDX Becton, Dickinson and Company | Maintains: Outperform | $275 → $270 | $227.68 | +18.59% | 3 | Aug 2, 2024 | |
| AXGN Axogen | Initiates: Outperform | $13 | $15.64 | -16.88% | 1 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $89 | $98.22 | -9.39% | 25 | Jan 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $8.89 | +12.49% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $172 → $175 | $144.47 | +21.13% | 20 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $178.16 | +52.11% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.24 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $35.91 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $74.81 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.50 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $81.03 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $0.46 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $71.65 | +20.03% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.43 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $21.80 | - | 3 | Jan 2, 2018 |
Masimo
Nov 6, 2024
Upgrades: Outperform
Price Target: $170
Current: $169.52
Upside: +0.28%
DexCom
Oct 25, 2024
Maintains: Strong Buy
Price Target: $115 → $99
Current: $80.04
Upside: +23.69%
Zimmer Biomet Holdings
Oct 14, 2024
Maintains: Outperform
Price Target: $128 → $123
Current: $107.12
Upside: +14.82%
Intuitive Surgical
Oct 14, 2024
Maintains: Outperform
Price Target: $500 → $540
Current: $524.43
Upside: +2.97%
Insulet
Oct 14, 2024
Maintains: Outperform
Price Target: $213 → $260
Current: $266.57
Upside: -2.46%
Abbott Laboratories
Oct 14, 2024
Maintains: Outperform
Price Target: $122 → $129
Current: $114.23
Upside: +12.93%
ICU Medical
Sep 12, 2024
Maintains: Outperform
Price Target: $158 → $190
Current: $156.82
Upside: +21.16%
Boston Scientific
Sep 4, 2024
Maintains: Strong Buy
Price Target: $91 → $94
Current: $88.95
Upside: +5.68%
Becton, Dickinson and Company
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $227.68
Upside: +18.59%
Axogen
Jul 1, 2024
Initiates: Outperform
Price Target: $13
Current: $15.64
Upside: -16.88%
Jan 30, 2024
Maintains: Outperform
Price Target: $84 → $89
Current: $98.22
Upside: -9.39%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $8.89
Upside: +12.49%
Jan 3, 2024
Maintains: Outperform
Price Target: $172 → $175
Current: $144.47
Upside: +21.13%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $178.16
Upside: +52.11%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $9.24
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $35.91
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $74.81
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $29.50
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $81.03
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $0.46
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $71.65
Upside: +20.03%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.43
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $21.80
Upside: -